MeSH term
Frequency | Condition_Probility | Adult | 39 | 0.0 |
Aged | 20 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Blotting, Western | 12 | 0.0 |
Cells, Cultured | 27 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Humans | 168 | 0.0 |
Middle Aged | 31 | 0.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Anti-HIV Agents/pharmacology | 2 | 4.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Proteins/analysis/pharmacology/*physiology | 2 | 66.0 |
Recombinant Proteins | 4 | 0.0 |
Serine Proteinase Inhibitors/analysis/pharmacology/*physiology | 2 | 100.0 |
Statistics, Nonparametric | 5 | 0.0 |
Virulence | 3 | 1.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Proteins/*pharmacology | 11 | 15.0 |
Research Support, Non-U.S. Gov't | 114 | 0.0 |
U937 Cells | 2 | 0.0 |
Base Sequence | 18 | 0.0 |
DNA Primers | 3 | 0.0 |
Female | 65 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 49 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
Animals | 66 | 0.0 |
Gene Therapy | 3 | 0.0 |
Menstrual Cycle/*physiology | 2 | 3.0 |
*Acute-Phase Proteins | 2 | 1.0 |
Male | 52 | 0.0 |
*Oncogene Proteins | 2 | 3.0 |
Proteins/metabolism | 7 | 0.0 |
Time Factors | 8 | 0.0 |
Mast Cells/*enzymology | 3 | 11.0 |
Tissue Distribution | 3 | 0.0 |
Amino Acid Sequence | 18 | 0.0 |
Molecular Sequence Data | 29 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Proteins/*analysis | 5 | 3.0 |
Neutrophils/enzymology | 6 | 8.0 |
Oxidation-Reduction | 8 | 0.0 |
Proteins/*metabolism | 17 | 1.0 |
Substrate Specificity | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Acute Disease | 5 | 0.0 |
In Vitro | 12 | 0.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 2 | 3.0 |
Pancreatic Elastase/metabolism | 3 | 10.0 |
Protease Inhibitors/*metabolism | 3 | 17.0 |
alpha 1-Antitrypsin/metabolism | 4 | 8.0 |
Aging/*metabolism | 2 | 0.0 |
Anti-Infective Agents/*metabolism | 2 | 25.0 |
Comparative Study | 15 | 0.0 |
Muramidase/metabolism | 2 | 6.0 |
Reference Values | 3 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Phenotype | 7 | 0.0 |
Rats | 9 | 0.0 |
Transfection | 5 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Proteins/analysis | 5 | 3.0 |
Binding Sites | 5 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Epithelium/enzymology | 2 | 5.0 |
Protein Binding | 7 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Bronchoalveolar Lavage Fluid/chemistry | 5 | 7.0 |
Lung/*metabolism | 2 | 2.0 |
Mice | 22 | 0.0 |
Mice, Inbred C57BL | 8 | 0.0 |
Blotting, Western/methods | 3 | 1.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Pregnancy | 8 | 0.0 |
*Protein Biosynthesis | 10 | 2.0 |
Proteins/genetics | 7 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 4 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
Kinetics | 10 | 0.0 |
Leukocytes/*physiology | 2 | 3.0 |
Proteins/*genetics/metabolism | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Chromatography, Affinity | 3 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Molecular Weight | 8 | 0.0 |
Hamsters | 6 | 0.0 |
Macromolecular Substances | 3 | 0.0 |
Mesocricetus | 6 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 14 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Aerosols | 6 | 8.0 |
Serine Proteinase Inhibitors/*pharmacology | 14 | 33.0 |
Sheep | 10 | 1.0 |
Drug Interactions | 2 | 0.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
*Disease Transmission, Vertical | 2 | 2.0 |
Infant, Newborn | 5 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Gene Expression/drug effects/immunology | 2 | 5.0 |
Glucocorticoids/pharmacology | 3 | 2.0 |
Leukocyte Elastase/metabolism | 4 | 18.0 |
Trachea | 2 | 7.0 |
Drug Synergism | 3 | 0.0 |
Escherichia coli/*drug effects | 3 | 27.0 |
Recombinant Proteins/pharmacology | 13 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Epithelial Cells/drug effects/*metabolism | 2 | 8.0 |
Proteins/genetics/*metabolism | 5 | 1.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Serine Proteinase Inhibitors/genetics/*metabolism | 4 | 66.0 |
alpha 1-Antitrypsin/pharmacology | 4 | 30.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Serine Proteinase Inhibitors/*genetics | 8 | 30.0 |
Succinimides/pharmacology | 2 | 16.0 |
Enzyme-Linked Immunosorbent Assay/methods | 4 | 1.0 |
Interleukin-6/analysis | 2 | 2.0 |
Leukocyte Elastase/analysis | 5 | 27.0 |
Serine Proteinase Inhibitors/*analysis | 5 | 62.0 |
Lipopolysaccharides/pharmacology | 5 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Cell Line | 14 | 0.0 |
Analysis of Variance | 4 | 0.0 |
*Proteins | 42 | 9.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Viral Load | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
alpha 1-Antitrypsin Deficiency/*complications | 2 | 100.0 |
Adolescent | 10 | 0.0 |
Cytokines/blood | 3 | 1.0 |
Escherichia coli/immunology | 2 | 2.0 |
Cloning, Molecular | 6 | 0.0 |
Serine Endopeptidases/metabolism | 3 | 2.0 |
Signal Transduction/physiology | 2 | 0.0 |
Malawi | 2 | 12.0 |
Muramidase/analysis | 2 | 7.0 |
Risk Factors | 2 | 0.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Gene Therapy/*methods | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Proteins/*genetics | 6 | 0.0 |
Anti-Infective Agents | 2 | 33.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Antigen-Antibody Complex/immunology | 2 | 3.0 |
Capillary Permeability/physiology | 2 | 10.0 |
Disease Models, Animal | 4 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
NF-kappa B/metabolism | 4 | 0.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
Rats, Long-Evans | 2 | 4.0 |
DNA Primers/genetics | 2 | 0.0 |
Defensins | 2 | 14.0 |
Epithelial Cells/drug effects/metabolism | 3 | 3.0 |
Neutrophils/*metabolism | 3 | 1.0 |
HIV-1/*drug effects | 4 | 2.0 |
Pancreatic Elastase/analysis | 5 | 27.0 |
Peroxidase/analysis | 2 | 3.0 |
Serine Proteinase Inhibitors/analysis | 2 | 50.0 |
Serum Albumin/analysis | 2 | 1.0 |
Sputum/chemistry | 3 | 21.0 |
alpha 1-Antitrypsin/analysis | 6 | 6.0 |
Cell Proliferation | 2 | 1.0 |
Gene Expression Regulation | 6 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/*pharmacology | 2 | 11.0 |
Nitrites/metabolism | 2 | 4.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Proteins/*genetics/physiology | 2 | 2.0 |
Transcription, Genetic | 5 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Serine Proteinase Inhibitors/*metabolism | 12 | 52.0 |
Cell Line, Transformed | 3 | 0.0 |
Macrophages/drug effects/*metabolism | 2 | 3.0 |
Recombinant Proteins/therapeutic use | 4 | 1.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Heparin/pharmacology | 5 | 2.0 |
Trypsin/metabolism | 2 | 1.0 |
Guinea Pigs | 3 | 0.0 |
Proteins/administration & dosage/*pharmacology | 2 | 50.0 |
Serine Proteinase Inhibitors/administration & dosage/*pharmacology | 3 | 100.0 |
HIV Infections/*transmission | 2 | 3.0 |
Cattle | 6 | 0.0 |
Child | 4 | 0.0 |
Proteins/pharmacology | 3 | 4.0 |
Serine Proteinase Inhibitors/pharmacology | 3 | 6.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Proteins/*analysis/genetics | 2 | 8.0 |
Cell Division | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Neutrophils/metabolism | 3 | 2.0 |
Exons | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Serine Proteinase Inhibitors/*blood | 2 | 12.0 |
Organ Specificity | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Proteins/*therapeutic use | 2 | 100.0 |
Biological Markers/*analysis | 2 | 1.0 |
Injections, Intraperitoneal | 3 | 2.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Nasal Mucosa/*secretion | 2 | 33.0 |
Proteins/chemistry/*metabolism | 2 | 2.0 |
Thermodynamics | 3 | 0.0 |
Mice, Inbred C3H | 2 | 0.0 |
Cathepsins/antagonists & inhibitors/metabolism | 2 | 100.0 |
Pancreatic Elastase/antagonists & inhibitors/metabolism | 2 | 40.0 |
Leukocyte Elastase/*antagonists & inhibitors | 3 | 33.0 |
Leukocytes/*enzymology | 2 | 3.0 |
Swine | 3 | 0.0 |
Proteins/genetics/metabolism/*pharmacology | 2 | 50.0 |
Serine Endopeptidases/*metabolism | 4 | 4.0 |
Infant | 3 | 0.0 |
Endopeptidases/*metabolism | 2 | 1.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Respiratory Function Tests | 3 | 1.0 |
Salivary Proteins/*metabolism | 2 | 40.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Serine Proteinase Inhibitors/*biosynthesis/genetics | 3 | 75.0 |
Chloramines/pharmacology | 2 | 40.0 |
*Oxidative Stress | 2 | 0.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
alpha 1-Antitrypsin/*metabolism | 5 | 25.0 |
Bronchoalveolar Lavage Fluid | 3 | 6.0 |
Binding, Competitive | 2 | 0.0 |
HIV-1/*physiology | 2 | 0.0 |
Leukocyte Elastase/antagonists & inhibitors/metabolism | 2 | 100.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Epithelial Cells | 3 | 0.0 |
Serine Proteinase Inhibitors/genetics | 2 | 22.0 |
Pancreatic Elastase/*antagonists & inhibitors | 2 | 50.0 |
Protein Conformation | 3 | 0.0 |
Pepsin A/metabolism | 2 | 13.0 |
Child, Preschool | 3 | 0.0 |
Neutrophils/*enzymology | 2 | 1.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Cell Count | 4 | 0.0 |
Leukocytes/enzymology | 2 | 1.0 |
Phagocytosis/drug effects/*immunology | 2 | 18.0 |
Protease Inhibitors/analysis | 2 | 40.0 |
Interleukin-8/biosynthesis | 2 | 1.0 |
Up-Regulation/immunology | 2 | 1.0 |
Pulmonary Alveoli/pathology | 2 | 8.0 |
Serine Proteinase Inhibitors/*therapeutic use | 2 | 25.0 |
Lung/drug effects/*enzymology | 2 | 66.0 |
Half-Life | 2 | 0.0 |
Epithelium/metabolism | 3 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Trachea/cytology/*metabolism | 2 | 18.0 |
Leukocyte Elastase | 10 | 23.0 |
Neutrophils/drug effects/*enzymology | 2 | 15.0 |
Pancreatic Elastase/antagonists & inhibitors | 5 | 50.0 |
Serine Proteinase Inhibitors/*administration & dosage | 2 | 100.0 |
Lung/drug effects/*metabolism | 2 | 20.0 |
alpha 1-Antitrypsin/*analysis | 2 | 8.0 |
Chymotrypsin/antagonists & inhibitors | 2 | 20.0 |
Leukocytes/chemistry | 2 | 4.0 |
Pancreatic Elastase/*metabolism | 2 | 12.0 |
Adenoviridae/genetics | 3 | 0.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Gene Expression | 4 | 0.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Pancreatic Elastase/*pharmacology | 2 | 33.0 |
Glutathione/*metabolism | 2 | 3.0 |
Mutation | 3 | 0.0 |
Serine Proteinase Inhibitors | 2 | 22.0 |
Injections, Intravenous | 3 | 0.0 |
Administration, Topical | 2 | 1.0 |
Mice, SCID | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
